Respiratory And Thoracic Cancers

Tesevatinib Gains Orphan Drug Status for EGFR-Mutation Positive NSCLC

By August 07, 2017

In March 2016, tesevatinib was designated Orphan Drug status for the treatment of autosomal recessive polycystic kidney disease (ARPKD).

Regular Thyroxine Use May Raise Thyroid Cancer Risk

July 31, 2017

Compared with controls, cases were more likely to have been previously diagnosed with hypothyroidism (adjusted odds ratio, 3.01).

FDA Approves Combo Tx for Metastatic NSCLC with BRAF V600E Mutation

By June 23, 2017

The approval for Tafinlar and Mekinist combination therapy was based on a Phase 2 international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial (Study BRF113928) in patients with locally confirmed stage IV NSCLC with BRAF V600E mutation.

Progression Free Survival with Nivolumab in Recurrent NSCLC

June 22, 2017

The researchers found that the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy among the 423 patients with a PD-L1 expression level of 5% or more.

Two New Meds May Improve Advanced NSCLC Survival Rates

June 06, 2017

The second clinical trial compared dacomitinib to the current standard targeted drug gefitinib in treating epidermal growth factor receptor-positive NSCLC.

Zykadia Approved for First-Line ALK-Positive Metastatic NSCLC

By May 30, 2017

The FDA approval was based on data from the Phase 3, open-label, randomized, multicenter, global ASCEND-4 trial.

Findings 'Strongly Suggest' Cigarette Filters Behind Rise in Lung CA

May 23, 2017

The new report recommends that the U.S. Food and Drug Administration should consider a ban on ventilating filters.

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

FDA Approves Keytruda Combo Tx for First-Line NSCLC

By May 11, 2017

The approval marks Keytruda as the only anti-PD-1 agent approved in the first-line setting as both monotherapy and combination therapy for appropriate patients with metastatic NSCLC.

Progression Free Survival in NSCLC Assessed With Selumetinib Addition

May 10, 2017

For selumetinib + docetaxel and placebo + docetaxel, median progression-free survival was 3.9 and 2.8 months, respectively.

Alunbrig Granted Accelerated Approval for Metastatic NSCLC

By April 28, 2017

Overall response rate for brigatinib in the 90mg arm was 48% (95% CI: 39%, 58%) and was 53% (95% CI: 43%, 62%) in the 180mg arm

FDA Grants Lorlatinib Breakthrough Therapy Designation for NSCLC

By April 28, 2017

Pfizer has begun enrolling patients in a Phase 3 study of lorlatinib, called 'CROWN'. The trial will be an open-label randomized, two-arm study comparing lorlatinib to crizotinib in the first-line treatment of patients with metastatic ALK-positive NSCLC.

Distinction Between Cancer Occurrence in U.S.-, African-Born Blacks

April 14, 2017

Research suggests differences in environmental, cultural, social, genetic factors

Alectinib Improves Progression-Free Survival in NSCLC Study

April 10, 2017

The ALEX study is intended to convert Alecensa to full approval as an initial treatment.

Environmental Toxins Linked to Multiple Diseases, Early Puberty

By April 07, 2017

These studies identified links to increased risks of thyroid, testicular and breast cancer, nonalcoholic fatty liver disease and even the early onset of puberty for boys, which can lead to diseases in adulthood.

Childhood Survivors May be Predisposed to Cancer Later in Life

April 05, 2017

More than one-quarter of patients who survived childhood cancer had developed another cancer by the age of 45.

Five-Year Survival Rate Assessed for Nivolumab in NSCLC

April 03, 2017

Of the 16 patients who survived at least 5 years, 9 were male, 12 were current smokers at baseline.

Thyroid Cancer Incidence, Mortality Assessed for Last 40 Years

April 03, 2017

The researchers found that there was an increase in the incidence of thyroid cancer, on average by 3.6% per year during 1974 to 2013.

Tagrisso Gains Regular FDA Approval for NSCLC

By March 31, 2017

The approval is based on results from the AURA3 trial, which found an improvement in investigator-assessed progression-free survival with Tagrisso when compared to a platinum-based doublet chemotherapy group.

Are Antiemetic Prophylactics Being Overprescribed for Chemotherapy?

By March 24, 2017

Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.

Recurrence Biomarker ID'd in Locally-Advanced NSCLC

March 21, 2017

At a median follow-up of 10.9 months, the researchers found that 46% of locally-advanced non-small cell lung cancer patients recurred at a median time of 7.6 months after chemoradiation.

Improving Patient Knowledge Surrounding Lung CA Screening

March 20, 2017

One shared decision-making visit was shown to improves patient knowledge of eligibility criteria, benefits, harms of screening with low-dose CT.

Body Weight Linked to GI Cancer Risk

March 16, 2017

The research found that those who gain more than 40 pounds by age 50 may double their risk of esphageal adenocarcinoma and moderately increased their risk for gastric cardia adenocarcinoma.

Massage Improves Pain, Lymphedema in Female CA Patients

March 10, 2017

The researchers found that all participants reported a positive experience with aromatherapy massage.

Experience of Patients With Thyroid CA Who Decide Not to Intervene

March 10, 2017

The researchers found that 18 of the people interviewed had elected not to intervene on their thyroid finding, and they had been living with the decision for a mean of 39 months.

Pembrolizumab for Malignant Pleural Mesothelioma

By March 10, 2017

Alley, EW et al. "Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial"

FDA to Review Ready-to-Dilute Pemetrexed Formulation

By February 28, 2017

The FDA has accepted for review the New Drug Application (NDA) for Eagle's ready-to-dilute (RTD) Pemetrexed Injection 25mg/mL for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer and mesothelioma (in combination with cisplatin).

FDA Grants Opdivo Accelerated Approval For Urothelial Carcinoma

By February 03, 2017

The FDA has approved Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-based chemotherapy or for those who have disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.

Young Thyroid CA Survivors At-Risk for Serious Disorders in Later Life

January 25, 2017

Younger survivors of thyroid cancer are at increased risk for certain types of health problems later in life, according to a study presented at the American Society of Clinical Oncology's Cancer Survivorship Symposium, held from January 27 to 28 in San Diego.

Many NSCLC Patients Are Being Overlooked for Life Prolonging Treatment

January 24, 2017

Many U.S. patients with late-stage non-small-cell lung cancer (NSCLC) do not receive treatments that could prolong their lives, according to a study published online January 18 in the Journal of Thoracic Oncology.